PMVP Filings — Pmv Pharmaceuticals, Inc. - FilingSpy
PMVP
Pmv Pharmaceuticals, Inc.
A precision oncology company developing small-molecule drugs that fix a broken "guardian of the genome." The p53 protein normally stops cancer cells from growing, but mutations disable it in many tumors; PMV's therapies, including its lead candidate rezatapopt, aim to structurally correct these mutant proteins so they work again. Founded in 2013 by scientists including Arnold Levine, who discovered p53 in 1979, the company was originally incorporated as PJ Pharmaceuticals.
Alland LeilaChief Medical Officer · 6 transactions
+1047.7%
45.9Kas of Sep 2023
56.2K
—
10.3K
Kung WinstonCOO, CFO · 3 transactions
+60.6%
10.6Kas of Nov 2022
4.0K
—
—
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -2.41M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.